Shaken baby syndrome in an infant treated for retinopathy of prematurity with anti-VEGF injection
No Thumbnail Available
Date
2023
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
We present the case of an infant who received bevacizumab treatment for retinopathy of prematurity (ROP) and developed retinal hemorrhages 12 weeks later. Although preretinal hemorrhages along the ROP's ridge were a concern for recurrence, we decided to investigate other etiologies because of numerous retinal hemorrhages in different retinal layers and their concentration in the posterior pole. Cranial magnetic resonance imaging revealed a new-onset subdural hemorrhage. Factors that were suspicious for trauma were identified in the detailed history taken from the family by the hospital's child abuse team. This case highlights the importance of considering the characteristics of retinal hemorrhages in infants with ROP and conducting any necessary investigation. © 2022 American Association for Pediatric Ophthalmology and Strabismus
Description
Keywords
Angiogenesis Inhibitors , Bevacizumab , Child , Gestational Age , Humans , Infant , Infant, Newborn , Intravitreal Injections , Laser Coagulation , Retinal Hemorrhage , Retinopathy of Prematurity , Shaken Baby Syndrome , bevacizumab , vasculotropin antibody , angiogenesis inhibitor , bevacizumab , Article , case report , clinical article , electroencephalogram , follow up , human , infant , laser therapy , male , necrotizing enterocolitis , neonatal intensive care unit , nuclear magnetic resonance imaging , ophthalmoscopy , physical abuse , respiratory distress syndrome , retina angiography , retina hemorrhage , retrolental fibroplasia , shaken baby syndrome , subdural hematoma , treatment duration , venous congestion , adverse event , child , complication , gestational age , intravitreal drug administration , laser coagulation , newborn , retina hemorrhage , retrolental fibroplasia , shaken baby syndrome